IP Library Granted Patent US 10,035,839
Granted Patent B2
US 10,035,839 · App. 15/434,477 · Granted Jul 31, 2018

Blood glucose lowering compound

Inventors: David Bruce Baldwin (Carmel, IN); John Michael Beals (Indianapolis, IN); Andrew Ihor Korytko (Oceanside, CA); Bryant Rhodius McLaughlin (Millbrae, CA); Volker Schellenberger (Palo Alto, CA)
Assignees: Eli Lilly and Company; Amunix Operating Inc.
C07K14/72A61K38/179A61K38/1796A61K38/28A61K47/64C07K14/62C07K14/71C07K2319/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,035,839
App. No.
15/434,477
Granted
Jul 31, 2018
Kind
B2
Abstract

The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound. The compound claimed herein comprises an A chain and a B chain, wherein the amino acid sequence of the A chain is SEQ ID NO: 1 and the amino acid sequence of the B chain is SEQ ID NO: 2.

Claims (6)

1. A compound comprising an A chain and a B chain, wherein the amino acid sequence of the A chain is SEQ ID NO: 1 and the amino acid sequence of the B chain is SEQ ID NO: 2, and wherein the A and B chains contain a disulfide bond between the cysteine at position 7 of the A chain and the cysteine at position 7 of the B chain, a disulfide bond between the cysteine at position 20 of the A chain and the cysteine at position 19 of the B chain, and a disulfide bond between the cysteine at position 6 of the A chain and the cysteine at position 11 of the A chain.

2. A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutically acceptable excipients.

3. A method of treating diabetes in a patient comprising administering to a patient in need thereof an effective amount of the compound of claim 1 .

4. A method of treating diabetes in a patient comprising administering to a patient in need thereof an effective amount of the composition of claim 2 .

5. A method of treating hyperglycemia in a patient comprising administering to a patient in need thereof an effective amount of the compound of claim 1 .

6. A method of treating hyperglycemia in a patient comprising administering to a patient in need thereof an effective amount of the composition of claim 2 .

Assignments (5)
CHANGE OF NAME Recorded Feb 4, 2021
From: AMUNIX OPERATING INC.
To: AMUNIX PHARMACEUTICALS, INC.
Reel/Frame 055223/0978 →
CHANGE OF NAME Recorded Sep 28, 2020
From: AMUNIX OPERATING INC.
To: AMUNIX PHARMACEUTICALS, INC.
Reel/Frame 053906/0940 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2020
From: MCLAUGHLIN, BRYANT R.; SCHELLELNBERGER, VOLKER
To: AMUNIX PHARMACEUTICALS, INC.
Reel/Frame 053846/0992 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2020
From: KORYTKO, ANDREW IHOR; BEALS, JOHN MICHAEL; BALDWIN, DAVID BRUCE
To: ELI LILY AND COMPANY
Reel/Frame 053852/0411 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2018
From: ELI LILLY AND COMPANY
To: AMUNIX OPERATING INC.
Reel/Frame 046538/0070 →
Continuity (2)
Provisional Application 62299131 · Feb 24, 2016
Related Publication 20170240614A1 · Aug 24, 2017